Literature DB >> 10473225

Intracellular activity of trovafloxacin against Staphylococcus aureus.

P J van den Broek1, T G Koot, E van Strijen, H Mattie.   

Abstract

The effect of trovafloxacin on Staphylococcus aureus ingested by human granulocytes or monocytes was compared with that on S. aureus in cell-free medium. Maximum growth inhibition (E(R,max)) by the antibiotic was 0.530 log10/h for S. aureus within granulocytes, 0.912 log10/h for S. aureus within monocytes, and 1.830-1.916 log10/h for S. aureus in medium. EC50, the concentration at which 50% of the maximum growth inhibition is achieved, did not differ significantly under the conditions investigated. After inhibition of intracellular killing by granulocytes with sodium fluoride, the intracellular antibacterial activity of trovafloxacin was still less than that in medium. A 3.4 times higher concentration was needed to achieve the same effect on phagocytosed S. aureus as in cell-free medium. Trovafloxacin binds more strongly to granulocytes than to monocytes, the respective cellular concentrations being 10 and four times higher than that in medium. In conclusion, the activity of trovafloxacin against S. aureus ingested by human granulocytes or monocytes is less than that against S. aureus in cell-free medium and is not related to the cell-associated concentration. Intracellular conditions are not favourable for the antibacterial activity of trovafloxacin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473225     DOI: 10.1093/jac/44.2.193

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever.

Authors:  M Hussein Gasem; Monique Keuter; Wil M V Dolmans; Johanna Van Der Ven-Jongekrijg; Robert Djokomoeljanto; Jos W M Van Der Meer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.

Authors:  L E Stearne; I C Gyssens; W H Goessens; J W Mouton; W J Oyen; J W van der Meer; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils.

Authors:  Rodolphe Garraffo; Thibaud Lavrut; Jacques Durant; Laurence Héripret; Marie-Ange Sérini; Brigitte Dunais; Pierre Dellamonica
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.